Chris Brennan

Chris Brennan has a diverse work experience that spans across multiple industries. In 2018, they completed an internship at Amgen. From 2013 to 2019, they worked as a PhD student at the Massachusetts Institute of Technology, studying the effects of aneuploidy on protein aggregation and protein homeostasis. Chris then joined Pfizer in 2019 as a Postdoctoral Research Fellow, where they stayed until 2022. Currently, Chris Brennan is working at Entrada Therapeutics as a Scientist II, starting in 2022.

Chris Brennan's education history includes earning a Bachelor of Science degree in Biology, General from Providence College, which they completed from 2009 to 2013. Following this, they pursued further studies at the Massachusetts Institute of Technology and obtained a Doctor of Philosophy (PhD) degree in Biology, General from 2013 to 2019.